Biosimilars to Surpass Valuation of US$ 85 Bn by 2031: Notes TMR Study

June 17, 2022

Demand for recombinant non-glycosylation proteins in biosimilars market rising on back of need for advanced and affordable treatments for chronic diseases worldwide; application of cutting-edge technologies to expand avenues Patent expiry of several important biological drugs to spur revenue potential in biosimilar production; Europe emerged as remarkably lucrative market and will continue to witness profitable opportunities ALBANY, N.Y. , June 13, The market value of the biosimilars is steadily growing due to their growing acceptance worldwide in managing chronic and life-threatening diseases. Advancements in biotechnology have enabled pharmaceutical companies to capture revenues from a growing number of product approvals, especially …

Read the source article at PR Newswire
2022-06-13 15:30:00

Share This Story!